Aliskiren/amlodipine/hydrochlorothiazide

Drug Profile

Aliskiren/amlodipine/hydrochlorothiazide

Alternative Names: Amlodipine/aliskiren/hydrochlorothiazide; Amlodipine/hydrochlorothiazide/aliskiren; Amturnide; Hydrochlorothiazide/aliskiren/amlodipine; Hydrochlorothiazide/amlodipine/aliskiren; Rasitrio; Tekturna®-amlo-HCTZ SPC

Latest Information Update: 12 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Amides; Antihypertensives; Benzothiadiazines; Dihydropyridines; Fumarates; Small molecules
  • Mechanism of Action Calcium channel antagonists; Renin inhibitors; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 12 Mar 2015 No recent reports on development identified - Phase-I for Hypertension (In volunteers) in India (PO)
  • 12 Mar 2015 No recent reports on development identified - Phase-III for Hypertension in Australia, Canada, Israel, Turkey and Egypt (PO)
  • 19 Apr 2012 Label updates completed following US FDA review of preliminary results from phase III ALTITUDE study in aliskiren
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top